ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Open-labeled, multicenter, phase I/II study of imatinib combined with ESHAP as salvage therapy in relapsed/refractory non-Hodgkin's lymphoma
Lymphoma, Non-Hodgkin
DRUG: ESHAP-Imatinib
Number of Adverse Events, Adverse events are recorded and analyzed from the time of enrollment to last day of ESHAP-imatinib treatment, Up to 33 weeks
Phase I/II Overall Response Rate (ORR), Week 4, Week 10, Week 16|Phase II Event-Free Survival, Up to 3 years|Phase II Overall Survival, Up to 3 years
Open-labeled, multicenter, phase I/II study of imatinib combined with ESHAP as salvage therapy in relapsed/refractory non-Hodgkin's lymphoma